Mount Sinai Medical Center Physician Leads Global Phase 3 Trial Showing Chemotherapy-Free Treatment Improves Outcomes for Women with dMMR Endometrial Cancer

In the 299-patient Phase 3 KEYNOTE-C93 trial, pembrolizumab monotherapy reduced the risk of disease progression or death by 43% versus carboplatin-paclitaxel chemotherapy (hazard ratio 0.57) in advanced or recurrent dMMR endometrial cancer. Patients also reported improved quality of life, with no new safety signals; overall survival data remain immature and follow-up continues. The results suggest a potential chemotherapy-free first-line option for this subgroup, but do not establish a change in treatment standard.

Analysis

The key commercial distinction is substitution, not a new drug market: pembrolizumab is already used in frontline treatment, so monotherapy could change the regimen for dMMR patients without necessarily adding many new starts for Merck. The revenue effect depends on treatment duration and uptake versus current pembrolizumab-plus-chemotherapy practice—neither is quantified here. The chemotherapy-only comparator also leaves an important question for guideline adoption: how clinicians weigh pembrolizumab alone against the existing combination, rather than against chemotherapy alone.

Near term, the result supports a positive narrative for Merck’s oncology franchise, but likely has limited standalone valuation significance absent label or guideline changes and evidence of incremental treatment duration. Over 1–3 months, watch regulatory filings, guideline updates, and absolute PFS results; the reported relative risk reduction alone does not establish the size of the clinical or commercial benefit. Over 6–18 months, a chemotherapy-free option could improve tolerability and broaden patient/physician preference, while reducing use of generic carboplatin and paclitaxel. The dMMR subset limits the addressable population, and mature overall-survival data remain a key uncertainty.

Contrarian read: the headline may overstate incremental upside for Merck because the drug is already embedded in frontline care; the more consequential risk is whether monotherapy displaces the combination or only chemotherapy-alone use. Rival immunotherapy regimens, including GSK’s dostarlimab-based approach, remain competitive benchmarks. No standalone MRK trade is justified from this release alone; the thesis strengthens with clear label/guideline adoption and evidence of incremental duration, and weakens if practice remains combination-led or mature outcomes fail to support the PFS signal.

Key Decisions for Investors

• Do not chase MRK solely on the announcement; treat it as positive pipeline/franchise validation with uncertain incremental revenue.
• Put MRK on a catalyst watch for regulatory and guideline decisions, absolute PFS and treatment-duration data, and evidence on uptake versus pembrolizumab-plus-chemotherapy.
• Reassess the thesis if mature overall-survival data do not support the PFS benefit, or if clinicians continue to favor combination treatment; those outcomes would limit the chemotherapy-free opportunity.
• Monitor whether adoption shifts use away from generic carboplatin/paclitaxel, but avoid a direct short based on this study alone given the limited, biomarker-defined population.